Incyte (INCY) Given a $65.00 Price Target at Oppenheimer

Oppenheimer set a $65.00 price target on Incyte (NASDAQ:INCY) in a report published on Monday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Incyte’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at $0.39 EPS, Q3 2018 earnings at $0.14 EPS, Q4 2018 earnings at $0.33 EPS, FY2018 earnings at $0.62 EPS, FY2019 earnings at $1.93 EPS, FY2020 earnings at $2.72 EPS, FY2021 earnings at $4.25 EPS and FY2022 earnings at $5.63 EPS.

Several other research analysts have also recently commented on INCY. Raymond James Financial restated a buy rating on shares of Incyte in a report on Tuesday, December 12th. BidaskClub upgraded shares of Incyte from a strong sell rating to a sell rating in a report on Friday, January 26th. Zacks Investment Research cut shares of Incyte from a hold rating to a sell rating in a report on Tuesday, January 2nd. Credit Suisse Group set a $78.00 target price on shares of Incyte and gave the stock an outperform rating in a report on Friday, April 6th. Finally, ValuEngine upgraded shares of Incyte from a sell rating to a hold rating in a report on Thursday, March 1st. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Incyte currently has a consensus rating of Buy and an average price target of $119.66.

Incyte stock opened at $69.83 on Monday. The company has a market capitalization of $14,427.73, a PE ratio of 109.11 and a beta of 0.66. Incyte has a twelve month low of $61.30 and a twelve month high of $142.45. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01.



Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. The company had revenue of $444.20 million during the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The business’s quarterly revenue was up 36.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.05 earnings per share. equities research analysts predict that Incyte will post -0.13 EPS for the current fiscal year.

In other news, insider David W. Gryska sold 1,952 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total value of $167,013.12. Following the transaction, the insider now directly owns 12,922 shares of the company’s stock, valued at $1,105,606.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Reid M. Huber sold 1,958 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total transaction of $167,506.90. The disclosure for this sale can be found here. 17.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Exane Derivatives bought a new position in shares of Incyte in the fourth quarter valued at about $669,000. NuWave Investment Management LLC bought a new position in shares of Incyte in the fourth quarter valued at about $473,000. Ascend Capital LLC bought a new position in shares of Incyte in the fourth quarter valued at about $9,879,000. Financial Gravity Companies Inc. bought a new position in shares of Incyte in the fourth quarter valued at about $120,000. Finally, Emory University raised its position in shares of Incyte by 30.8% in the fourth quarter. Emory University now owns 17,046 shares of the biopharmaceutical company’s stock valued at $1,614,000 after purchasing an additional 4,016 shares during the period. 93.50% of the stock is currently owned by institutional investors.

WARNING: “Incyte (INCY) Given a $65.00 Price Target at Oppenheimer” was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://dakotafinancialnews.com/2018/04/13/incyte-incy-given-a-65-00-price-target-at-oppenheimer.html.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply